CND Life Sciences to Present at Biotech Showcase Investor Conference
Poised for Growth After Successful Launching First Skin-Based Test for Parkinson s
News provided by
Share this article
PHOENIX, Jan. 8, 2021 /PRNewswire/ CND Life Sciences (
cndlifesciences.com), an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, will participate in the 2021 virtual Biotech Showcase taking place during the 39th Annual J.P. Morgan Healthcare Conference (January 11-14, 2021). The company is capitalizing on a wave of forward momentum fueled by the first full-year of commercialization and adoption of its
for Parkinson s disease and other neurological disorders.
A new form of an Alzheimer’s disease protein in the fluid that surrounds the brain and spinal cord indicates what stage of the disease a person is in, and tracks with tangles of tau protein in the brain, according to a new study.
Tau tangles are thought to be toxic to neurons, and their spread through the brain foretells the death of brain tissue and cognitive decline. Tangles appear as the early, asymptomatic stage of Alzheimer’s develops into the symptomatic stage.
The discovery of so-called microtubule binding region tau (MTBR tau) in the cerebrospinal fluid could lead to a way to diagnose people in the earliest stages of Alzheimer’s disease, before they have symptoms or when their symptoms are still mild and easily misdiagnosed.